News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Seeking Alpha Balance sheet
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Oppenheimer Asset Management Inc. recently acquired a new stake of 179,480 shares in Keurig Dr Pepper, Inc (NASDAQ:KDP), valued at approximately $5.87 million during the second quarter. This move is part of broader institutional investment trends, with other major firms like Vanguard Group Inc. …
This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to develop distinct trading strategies. It highlights a strong near-term sentiment potentially leading to a long-term positive bias, with an exceptional risk-reward short setup. The analysis provides specific entry, target, and stop-loss levels …
Euronet Worldwide (EEFT) recently signed a multi-year SaaS agreement with Unibanca to deploy its CoreCard platform in Peru and filed a US$152.08 million ESOP shelf registration. The Unibanca deal emphasizes Euronet's strategy to expand software-driven payments and credit issuing, reinforcing its investment narrative amidst …
Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …
Walleye Trading LLC has made a new investment in Euronet Worldwide (NASDAQ:EEFT), purchasing 14,588 shares valued at approximately $1.07 million. Other institutional investors also adjusted their holdings, with a significant 91.6% of the stock owned by institutional investors and hedge funds. Analyst sentiment for …
NewEdge Advisors LLC significantly reduced its stake in Coeur Mining (NYSE:CDE) by 60% in the first quarter, selling 172,952 shares and retaining 115,143 shares. Despite this, institutional investors collectively own 63.01% of the company. Coeur Mining reported quarterly earnings that missed analyst expectations, though …
Sharemaestro market context Stored weekly price path 22 weeks +8.4%Assenagon Asset Management S.A. significantly reduced its stake in Keurig Dr Pepper (NASDAQ:KDP) by 82.7% in the second quarter, selling 216,061 shares. Following the sale, the firm now owns 45,040 shares valued at $1.47 million. Other institutional investors have shown mixed activity, with some …
Wall Street Zen upgraded Alto Neuroscience (NYSE:ANRO) from "strong sell" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a target price of $36.62. Shares opened at $32.14, near their 12-month high, and the company reported a quarterly loss of $0.65 …
Euroseas (ESEA) reported strong Q2 2026 earnings with increased net income and EPS, yet its stock price remained largely flat. This indicates market skepticism regarding the sustainability of its profitability, possibly due to concerns about funding for a large newbuild program and the age …
This article analyzes Coeur Mining Inc. (NYSE: CDE) focusing on behavioral patterns and institutional flows. It highlights strong near and mid-term sentiment, potential support at current levels, and an exceptional risk-reward setup targeting a 25.9% gain. The piece also details three AI-generated trading strategies—Position, …
Keurig Dr Pepper (KDP) has announced a major brand refresh for 7UP, focusing on a lime-first recipe and a new visual identity, targeting younger consumers. Additionally, KDP has partnered with Portillo's to introduce co-branded Dr Pepper Shake items for a limited time. These initiatives …
OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have reported an amended beneficial ownership stake in NeuroPace Inc. (NPCE). The entities collectively own 1,505,125 shares, representing 4.4% of NeuroPace's common stock as of June 30, 2026, and share both voting and dispositive power …
An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …
Van Eck Associates Corporation has disclosed a 6.5% beneficial ownership stake in Coeur Mining, Inc., holding 67,029,794 ordinary shares. This information comes from an amended Schedule 13G/A filing, indicating that Van Eck possesses sole voting and dispositive power over these shares. The filing emphasizes …
Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …
Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc., and Steven A. Cohen, has reported a beneficial ownership of 5.0% of Neuronetics, Inc.'s common stock, totaling 3,822,124 shares as of August 13, 2026. This disclosure was made in a new SEC ownership filing …
Euroseas reported a net income of $33.2 million in Q2 2026, driven by strong containership charter rates and low drydocking expenses, making it one of the company's most profitable quarters in 15 years. The company has expanded its newbuilding program to 12 feeder and …
Coeur Mining (CDE) stock has returned 56% over the last year but trades below its 52-week high, presenting a valuation that appears cheaper than the S&P 500 on earnings and more expensive on sales. This dual valuation is attributed to the company's high operating …
Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.
Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …
ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …
Search by ticker symbol or company name and select a result to open its chart.